The Bladder Cancer Partnering 2010-2015 report provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The Bladder Cancer Partnering 2010-2015 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 35 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of bladder cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bladder cancer technologies and products.
Bladder Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to bladder cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
In Bladder Cancer Partnering 2010-2015, the available deals are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in bladder cancer partnering
2.2. Bladder cancer partnering over the years
2.3. Bladder cancer partnering by deal type
2.4. Bladder cancer partnering industry sector
2.5. Bladder cancer partnering by stage of development
2.6. Bladder cancer partnering by technology type
Chapter 3 – Average deal terms for bladder cancer
3.2 Average deal terms for bladder cancer
3.3 Bladder cancer headline values with median calculation
3.4 Bladder cancer upfront values with median calculation
3.5 Bladder cancer milestone values with median calculation
3.6 Bladder cancer royalty rates with median calculation
Chapter 4 – Active bladder cancer dealmakers
4.2 Most active bladder cancer dealmakers
4.3. Top bladder cancer deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
Chapter 5 – Bladder cancer dealmaking directory
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
Figure 1: Bladder cancer partnering since 2010
Figure 2: Bladder cancer dealmaking activity– 2010 to 2015
Figure 3: Bladder cancer partnering by deal type since 2010
Figure 4: Bladder cancer partnering by industry sector since 2010
Figure 5: Bladder cancer partnering by stage of development since 2010
Figure 6: Bladder cancer partnering by technology type since 2010
Figure 7: Bladder cancer deals with a headline value
Figure 8: Bladder cancer deals with upfront payment values
Figure 9: Bladder cancer deals with milestone payments
Figure 10: Bladder cancer deals with royalty rates, %
Figure 11: Top bladder cancer deals by value since 2010
Figure 12: Big pharma – top 50 – bladder cancer deals 2010 to 2015
Figure 13: Big pharma bladder cancer deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – bladder cancer deals 2010 to 2015
Figure 15: Big biotech bladder cancer deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions